GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. | After its potential kidney ...

Chronic kidney disease (CKD): It is the gradual loss of ... Stage 3: Divided into 3a and 3b. Symptoms start at this stage. Stage 3a: eGFR between 45 and 59ml/min Stage 3b: eGFR between 30 and ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The FLOW phase 3b trial showed significant reductions ... need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

People with kidney disease may be at higher risk of anxiety and depression. But taking care of your mental health can have a positive effect on your outlook with kidney disease. Chronic kidney ...

“These patients often have concomitant cardiovascular disease, they have chronic kidney disease ... reviewing data from Ozempic’s phase 3b FLOW kidney outcomes trial, which found the Novo ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) ...